Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BANT undervalued and oversold
Moon shot?
Weeeeeee
ASCM fighting over the bid.. always a good sign
Immune Therapeutics, Inc. Announces Cytocom Conference Call
Source: InvestorsHub NewsWire
October 27, 2020 -- InvestorsHub NewsWire -- via Stock Investor Wire -- Cytocom will host a conference call and live audio webcast at 8:00 a.m. EDT on October 28th to discuss the merger with Cleveland BioLabs (NASDAQ: CBLI) and provide a strategic vision for the combined company. To access the conference call supported with slides, please dial 646-558-8656 with the meeting ID: 841 7826 2704 and passcode: 281020. The conference call can also be accessed at https://cleartrustonline.com/cytocom. Approximately two hours following the live event, a webcast replay of the conference call will be available on Cytocom’s website https://www.cytocom.com/investors/ for approximately 30 days.
Recently, Immune Therapeutics, Inc. (Ticker: IMUN) announced the signing of a definitive merger agreement between Cytocom and Cleveland BioLabs with the merger set to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions.
Cytocom shareholders will have a majority position in the newly combined entity, which the parties anticipate will continue to be listed on the Nasdaq under the ticker symbol: CBLI, and the initial Board of Directors for the combined company will consist of four members selected by Cytocom and three members selected by Cleveland BioLabs. The Boards of Directors of both companies have approved the combination.
For Immune Therapeutics, Inc. (Ticker: IMUN) and its shareholders who hold a considerable stake in Cytocom this means that the value for all of the years of support and collaboration with Cytocom can be realized. The Cytocom platform technologies and product pipeline, in combination with Cleveland BioLabs, have the potential to drive significant future growth in Immune’s shareholder value.
Each party to the proposed merger believes that the combined company will create near-term commercial opportunities in numerous areas of significant unmet medical needs including acute radiation injury, oncology, infectious disease, inflammation and autoimmune-mediated conditions, with multiple commercial, regulatory and clinical milestones expected over the next 12 to 18 months. Operating as “Cytocom, Inc.” and under the leadership of Cytocom’s experienced management team, the combined company will be positioned for consistent growth.
Overview
Michael K. Handley, President and Chief Executive Officer of Cytocom, stated, “Our merger with Cleveland BioLabs and its subsequent immune-focused platform will be a transformative growth opportunity for Cytocom and Cleveland BioLabs shareholders. We believe that the combination of these highly complementary late-stage pipelines will strengthen our position and advance our efforts to unlock the potential of immune-modulating agents in the treatment of serious medical conditions. Further, this merger will enhance our ability to become a recognized leader in immune-modulating treatments and builds on the momentum created by our recent acquisition of ImQuest Life Sciences. We plan to utilize the combined platform to further drive value with additional clinical and commercial products and continue to seek strategic partnerships and acquisitions.”
Dr. Andrei Gudkov, Chief Scientific Officer of Cleveland BioLabs, said: “This is an exciting day for Cleveland BioLabs and a great opportunity for our stockholders. The merger with Cytocom will allow us to add the strength of our science and bright perspectives associated with Entolimod development in cancer treatment and radiation defense arenas with a string of immunomodulators developed by Cytocom to form a powerful blend of conceptually and scientifically aligned products. We believe that the merger with Cytocom is the ideal way to unlock the value of our technology platform and our lead drug candidate, Entolimod, and I look forward to seeing this exciting new therapy advance through the clinic.”
Conditions
The proposed transaction is subject to customary closing conditions, including approval by the stockholders of Cleveland Biolabs, the shares of the combined company being approved for listing on Nasdaq and a registration statement under the Securities Act becoming effective. Cytocom and Cleveland Biolabs expect the transaction to close during the first quarter of 2021.
About Cytocom
Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Cytocom is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Specifically, Cytocom has four programs in late-stage clinical development in Crohn’s disease, Fibromyalgia, Multiple Sclerosis and Pancreatic Cancer. Cytocom believes that its technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels not achieved by other published immunotherapy approaches. Cytocom’s immunomodulatory technology restores the balance between the cellular (Th1) and the humoral (Th2) immune systems. Immune balance is regulated through T-helper cells that produce cytokines. The Th1 lymphocytes help fight pathogens within cells like cancer and viruses through interferon-gamma and macrophages. The Th2 lymphocytes target external pathogens like cytotoxic parasites, allergens, toxins through the activation of B-cells and antibody production to effect to dendritic cells, which are natural activators of killer T cells, also known as cytotoxic T cells, or CD8+ T cells. Furthermore, the Cytocom technology antagonizes the Toll-like Receptors to inhibit pro-inflammatory cytokines. To learn more about Cytocom, Inc., please visit www.cytocom.com
About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Cleveland BioLabs’ proprietary platform of Toll-like immune receptor activators addresses conditions such as radiation sickness and cancer treatment side effects. Cleveland Biolabs’ most advanced product candidate, Entolimod is being developed as a medical radiation countermeasure for preventing death from acute radiation syndrome and, through its joint venture with Everon Biosciences, LLC – Genome Protection, Inc. – for other anticancer and antiaging indications. Additionally, Cleveland BioLabs also conducts business in the Russian Federation through a joint venture with Joint Stock Company RUSNANO, Panacela Labs, Inc. Cleveland BioLabs maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, please visit http://www.cbiolabs.com
SOURCE: Stock Investor Wire
$IMUN big day tomorrow
Best election play right here
Actually looks like it's going to the moon.. solar bro.. replacing oil. JKS will probably be a trillion dollar company soon.
Squeeze to 500 within a year just watch
It's a runaway train just look at the chart
Gonna squeeze hard here through the election at least.. could squeeze to 500 or beyond IMO
When did that happen
Clearly you are distorting the facts because you said their must be 7 bil outstanding shares.. you knew that was not true when you said it.. you could have said they will increase to 7 bil. But you purposely lied in your post to scare people.. the only question I wonder is what is your reason to scare people away from investing here
Unique Logistics International (ATL) LLC
2727 Paces Ferry Road, SE
Atlanta, GA 30339 USAPhone:
Fax:404-767-0500
There is only 500 mil a/s
.25 close?
News tomorrow? Noticed every time we hit a bottom and start to bounce they release news next day.. let's see if I am right
Expecting a massive breakout
Could get crazy here tomorrow
Hold off and we can get some cheaper.. this will close around 07 IMO
They cant short it below the low of the day and I know plenty that are accumulating here for the news to come.. not worried about shorting makes more opportunity to make money here while we wait
Who's trying to call the bottom here? I am thinking 1230
Oh snap.. somebody got got hahah nice one
I think monday is gonna be huge.. if they PR the merger news it could be another 1000% day
With this low float we are gonna have some wild swings on the way up. Should be fun. So far 005 to 09 then back to 05 then to .10 .. so much money to be made here
This chart will be increasing lows daily until breakout now that we found our bottom
Last PR came at 1pm
I am loading on the bid all day
Guess the dumping is over :( maybe we will get one more dump i hope
Close above 05.. guaranteed
7:30 I'm gonna throw out a big bid of 1 mil and we take is thing up
Your fried bud.. better cover.
NSPX isn't one to play around with.. real company coming back after years of being dark
We are early on the news only 8k has been released no PR
Holding for 10 dollars
SEND IT!!!!!
I'll take millions more in the 2s.. keep dumping thanks
Nobody should wlbe shocked ... we called this if you sold only blame yourself
Will close over 05 today
Now the pros step in.. obviously taking shares from these nubs selling the good news.. lmao these nubs always amaze me.. sell the absolute bottom just quit trading now if you sold that dip
Share structure cant be changed for months 28 mil public float